Related Experiment Videos

Biology of the prostate

¹Department of Urology, Free University Hospital, Amsterdam, The Netherlands.

Progress in Clinical and Biological Research

|January 1, 1991

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.

European urology·1998

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.

Cancer·1993

The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.

The Prostate. Supplement·1992

The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.

Scandinavian journal of urology and nephrology. Supplementum·1991

Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.

The Journal of steroid biochemistry and molecular biology·1990

The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma.

Human pathology·1990

See all related articles